Literature DB >> 2667103

Ciprofloxacin in the elimination of enteric Salmonella carriage stage.

J Lähdevirta1.   

Abstract

According to the present experience, ciprofloxacin seems to be a new promising drug for the treatment of enteric salmonella carriage stage. This paper reviews results with ciprofloxacin and older drugs. While the cure rates in previous studies were about 70%, it was at least 90% with ciprofloxacin although the treatment time was shorter and the rate of side effects was lower. However the final place of ciprofloxacin on this indication needs to be investigated further.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2667103

Source DB:  PubMed          Journal:  Scand J Infect Dis Suppl        ISSN: 0300-8878


  5 in total

1.  Efficacy of the combination pivampicillin/pivmecillinam compared to placebo in the treatment of convalescent carriers of nontyphi Salmonella.

Authors:  B Svenungsson; E Ekwall; H B Hansson
Journal:  Infection       Date:  1990 May-Jun       Impact factor: 3.553

2.  Peroral ciprofloxacin therapy impairs the generation of a protective immune response in a mouse model for Salmonella enterica serovar Typhimurium diarrhea, while parenteral ceftriaxone therapy does not.

Authors:  Kathrin Endt; Lisa Maier; Rina Käppeli; Manja Barthel; Benjamin Misselwitz; Marcus Kremer; Wolf-Dietrich Hardt
Journal:  Antimicrob Agents Chemother       Date:  2012-02-21       Impact factor: 5.191

3.  Emergence of fluoroquinolone resistance in Campylobacter jejuni and Campylobacter coli in subjects from Finland.

Authors:  H Rautelin; O V Renkonen; T U Kosunen
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

4.  Drug resistance and biochemical characteristics of Salmonella from turkeys.

Authors:  C Poppe; J J Kolar; W H Demczuk; J E Harris
Journal:  Can J Vet Res       Date:  1995-10       Impact factor: 1.310

5.  Liposome-incorporated ciprofloxacin in treatment of murine salmonellosis.

Authors:  M Magallanes; J Dijkstra; J Fierer
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.